Shingles, a condition caused by the reactivation of the varicella-zoster virus—the same virus responsible for chickenpox—remains a significant health concern, particularly among older adults. After an individual recovers from chickenpox, the virus stays dormant in the nervous system and can reactivate years later, leading to shingles. The condition typically begins with localized pain, tingling, or burning sensations followed by a blistering rash. For some, the associated pain may persist long after the rash resolves, a complication known as post-herpetic neuralgia, which can severely impact sleep, mobility, and overall quality of life.

The risk of shingles increases with age as the immune system naturally weakens, with those over 50 being particularly susceptible. In England and Wales, approximately 50,000 people aged 70 and above are diagnosed annually, with the condition contributing to around 50 deaths each year. People with compromised immune systems—for example, those undergoing chemotherapy, taking immunosuppressive drugs, or living with conditions such as AIDS—also face heightened risk. While younger adults can develop shingles, it is less common and generally less severe in this group.

Shingles can lead to additional complications beyond nerve pain. When the condition affects the eye, it can cause inflammation that may threaten vision if not treated promptly. It can also impact hearing, balance, and the broader nervous system, particularly among those with weakened immunity.

To help reduce the risk of shingles and its complications, a vaccine known as Shingrix is widely available through the National Health Service (NHS) in the UK. Unlike some vaccines, Shingrix does not contain a live virus and cannot cause shingles. It works by boosting the immune system’s ability to keep the virus in check and prevent reactivation. Vaccination is recommended for adults aged 65 and for those between 70 and 79 who have not yet received the vaccine. Additionally, adults aged 18 and over with severely weakened immune systems are eligible for vaccination.

The NHS vaccination program requires two doses of Shingrix for optimal protection. Most recipients may experience mild side effects such as soreness, redness, or swelling at the injection site, with some reporting tiredness, headaches, muscle aches, or mild fever lasting a day or two. Research indicates that the vaccine significantly reduces the risk of developing shingles as well as the incidence of prolonged nerve pain. While no vaccine guarantees complete immunity, those vaccinated who do contract shingles generally experience less severe symptoms.

Healthcare professionals advise that even individuals who have previously had shingles should consider vaccination, as prior infection does not ensure lifelong immunity. Those eligible for the vaccine should expect an invitation from their GP surgery. If no invitation is received or an appointment is missed, patients are encouraged to contact their healthcare provider to confirm eligibility and arrange vaccination.

Experts emphasize that vaccination is a straightforward and effective method to protect against shingles and its potentially debilitating effects, contributing to the maintenance of health and independence in older adults.